Hasil Pencarian - Steven Knapper

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia

    The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia oleh Steven Knapper

    Diterbitkan 2015-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine

    The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine oleh Elisabeth J. Walsby, Steven J. Coles, Steven Knapper, Alan K. Burnett

    Diterbitkan 2011-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL

    S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM... oleh Steven Knapper, Abin Thomas, Sophie King, Ian Thomas, Amanda Gilkes, Sarah Irwin, Robert Sellar, Simone Green, Ulrik Malthe Overgaard, Priyanka Mehta, Mike Dennis, Sylvie Freeman, Nigel Russell

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL

    P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT... oleh Nigel Russell, Oliver Cumming, Jad Othman, Richard Dillon, Nicola Potter, Charlotte Wilhelm-Benartzi, Jelena Jovanovic, Amanda Gilkes, Leona Batten, Joanna Canham, Emily Laura Hinson, Panagiotis Kottaridis, Jamie Cavenagh, Claire Arnold, Mike Dennis, Steven Knapper

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    P863: AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

    P863: AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIP... oleh Emma Searle, Jim Cavet, Steven Knapper, Ceri Bygrave, Victoria Campbell, Dima El-Sharkawi, Charlotte Pawlyn, Maria Creignou, Harriet S. Walter, David Valcarcel, Marta Hidalgo, Tomasz Knurowski, Karen Clegg, Neil Pegg, Will West, Debbie Haynes, Kris Frese, Tim C. P. Somervaille

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL

    S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 T... oleh Nigel Russell, Jad Othman, Richard Dillon, Nicola Potter, Charlotte Wilhelm-Benartzi, Steven Knapper, Leona Batten, Joanna Canham, Emily Laura Hinson, Ulrik Malthe Overgaard, Amanda Gilkes, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie Freeman, Mike Dennis

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY

    S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY oleh Francesco Passamonti, Andrea Patriarca, Steven Knapper, Candido Rivera, Joseph M Scandura, Timothy Devos, Nikki Granacher, Adam Mead, Stephen Oh, Jeanne Palmer, Raajit K Rampal, Lino Teichmann, Qing LI, Jean-Pierre Eliane, Tzuu-Wang Chang, Sandra Klein, Gozde Colak, Claire Harrison

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

    Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia oleh Paul Milne, Charlotte Wilhelm-Benartzi, Michael R. Grunwald, Venetia Bigley, Richard Dillon, Sylvie D. Freeman, Kathleen Gallagher, Amy Publicover, Sarah Pagan, Helen Marr, Gail L. Jones, Anne M. Dickinson, Angela Grech, Alan K. Burnett, Nigel H. Russell, Mark Levis, Steven Knapper, Matthew Collin

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES

    P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES oleh Nicola Potter, Jelena Jovanovic, Adam Ivey, Abin Thomas, Charlotte Wilhelm-Benartzi, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Steven Knapper, Asim Khwaja, Mary Frances Mcmullin, Jamie Cavenagh, Ulrik Malthe Overgaard, Richard Clark, Ellen Solomon, Sylvie Freeman, Robert Hills, Alan Burnett, Nigel Russell, Richard Dillon

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis

    Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis oleh Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, Rebecca H. Boucher, Aimee Jackson, Rachel S. Fletcher, Dorian Forte, Jose-Ezequiel Martin, Sonia Fox, James Roberts, Rachel Glover, Erica Harris, Hannah R. Bridges, Luigi Grassi, Alba Rodriguez-Meira, Adam J. Mead, Steven Knapper, Joanne Ewing, Nauman M. Butt, Manish Jain, Sebastian Francis, Fiona J. Clark, Jason Coppell, Mary F. McMullin, Frances Wadelin, Srinivasan Narayanan, Dragana Milojkovic, Mark W. Drummond, Mallika Sekhar, Hesham ElDaly, Judy Hirst, Maike Paramor, E. Joanna Baxter, Anna L. Godfrey, Claire N. Harrison, Simón Méndez-Ferrer

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: